Clinical trial

Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

NCT04221542

Study summary

ClinicalTrials.gov

Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

Design: INTERVENTIONAL · Status: RECRUITING · Phase: PHASE1

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

3 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Unmapped registry intervention AMG 509 Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Abiraterone Normalized identity: abiraterone View linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Enzalutamide Normalized identity: enzalutamide View linked drug · Find medicine records · Find other trials using this name

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2020-03-04

PhasePHASE1

Conditions

Prostate Cancerverified · MONDO: prostate cancer

Interventions

AMG 509DRUG

AbirateroneDRUG · verified · RxNorm: abiraterone

EnzalutamideDRUG · verified · RxNorm: enzalutamide

Sponsors & collaborators

Amgenlead sponsor

BeiGenecollaborator

BeOne (China only)collaborator

Mapped research locations

SeoulSouth Korea2 MadridSpain2 LisbonPortugal2 BarcelonaCatalonia, Spain2 New YorkNew York, United States1 HoustonTexas, United States1 PhiladelphiaPennsylvania, United States1 St LouisMissouri, United States1 AtlantaGeorgia, United States1 NashvilleTennessee, United States1 San FranciscoCalifornia, United States1 SeattleWashington, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04221542 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.